Revolutionary Cancer Treatment Could Reach Public in 2027

A groundbreaking cancer treatment developed in Wellington has shown promising results, giving hope to patients with terminal diagnoses. The innovative CAR T-cell therapy could be integrated into the New Zealand healthcare system by 2027, contingent on regulatory approvals and governmental funding.

BioOra Limited, a biotech firm partly owned by the Malaghan Institute of Medical Research, is preparing to manufacture the therapy, which has the potential to transform the lives of patients who are currently seeking expensive treatment options abroad. The company is constructing a state-of-the-art facility in Christchurch to enable rapid production of the therapy once clinical trials are completed.

John Robson, managing director of BioOra, expressed concern that the public health system may not respond swiftly enough to the treatment’s potential, risking both patient lives and the company’s progress. “We are on this knife edge of whether they will act quickly enough for us,” Robson stated. “Quarter 1 of 2027 is a distinct possibility for public access, but it has to align with a funding stream.”

The CAR T-cell therapy involves collecting a patient’s immune cells, genetically modifying them to target and destroy cancer cells, then reintroducing them into the bloodstream. This method has become a standard treatment for certain blood cancers in countries such as Australia but is not yet available in New Zealand.

The Malaghan Institute’s clinical trials have yielded strong results so far, with over half of lymphoma patients experiencing remission within months. Notably, the therapy exhibited lower rates of severe side effects when compared to existing commercial options, allowing for outpatient administration and reducing overall treatment costs.

As the ongoing phase 2 trial approaches its conclusion, BioOra is actively raising funds to establish its manufacturing base. The facility is designed to meet international standards for good manufacturing practice (GMP), ensuring the production of safe and effective therapies. Robson anticipates that the facility will be operational by the end of 2026, coinciding with the completion of the clinical trials.

In the first year of operation, BioOra aims to produce enough CAR T-cell therapy for 160 patients, increasing production to over 300 patients in the second year. The company is currently sourcing approximately $30–45 million in capital to support its expansion.

Public access to the treatment hinges on timely governmental support, as obtaining funding could facilitate immediate patient access while a more permanent solution is developed through Health NZ. Robson emphasized that the upfront costs of CAR T-cell therapy are justified by its potential to save millions in long-term healthcare costs, as it offers a one-time treatment option compared to ongoing, expensive interventions like chemotherapy.

Despite the anticipated challenges, BioOra is exploring avenues for private healthcare access prior to receiving regulatory approval from Medsafe, the New Zealand Medicines and Medical Devices Safety Authority. The company is engaged in discussions with interested private health providers to expedite the availability of CAR T-cell therapy.

Additionally, the Malaghan Institute has launched a fundraising campaign to finance the phase 2 trial, which is expected to cost over $17 million. This financial strategy is separate from the funding BioOra is securing through private investments.

Looking ahead, BioOra envisions expanding its production capabilities to cater to a wider range of conditions, including childhood acute lymphoblastic leukaemia and various autoimmune diseases. The company’s ambition is to establish New Zealand as a global hub for immunotherapy, potentially attracting international patients seeking advanced treatments.

Robson concluded by highlighting the importance of swiftly proving the therapy’s effectiveness and securing compassionate access. “It would be abhorrent for it not to be available immediately after the trial,” he stated, underlining the urgency of bringing this life-changing treatment to those in need.

As discussions about regulatory frameworks and funding pathways continue, the Cancer Control Agency, Te Aho o Te Kahu, is working alongside various health authorities to ensure a coordinated approach to introducing CAR T-cell therapy into the healthcare system. New legislation, the Medical Products Bill, is set to be introduced later this year, potentially paving the way for more flexible approval processes for innovative treatments like CAR T-cell therapy, although the full implementation may not occur until late 2030.